| Cat.No. | Name | Information |
|---|---|---|
| M2050 | GSK2636771 | GSK2636771 is a potent, orally available and specific PI3K p110β (PI3K beta, PI3Kβ) inhibitor. |
| M1925 | LY294002 | LY294002 is a highly selective PI3K inhibitor with IC50 values of 0.31, 0.73, 1.06 and 6.60 μM for PI3Kβ, PI3Kα, PI3Kδ and PI3Kγ respectively. LY294002 also inhibits CK2 with an IC50 of 98 nM. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. |
| M2296 | 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM, respectively. |
| M1715 | GDC-0941 (Pictilisib) | GDC-0941 is a selective and potent inhibitor of Class I PI3K, p110a IC50=0.003uM, U87MG IC50=0.95μM. |
| M1984 | PF-04691502 | PF-04691502 is a potent and selective, ATP-competitive PI3K/mTOR inhibitor with IC50 of 7.5 nM and 3.8 nM of AKT T308 and AKT S473, respectively. |
| M2053 | Wortmannin (KY 12420) | Wortmannin (KY 12420) is a specific, covalent inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase) with IC50 of 3 nM. |
| M1680 | BKM120 (Buparlisib) | BKM120 (NVP-BKM120) is a potent and highly specific oral pan-class I PI3K inhibitor. |
| M1819 | A66 | A66 is a potent and specific inhibitor of PI3K p110α with IC50 values of 32, 30 and 43 nM for p110α, p110α/E545K and p110α/H1047R. |
| M1671 | BEZ235 | BEZ235 (NVP-BEZ235) is a potent dual PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively. |
| M1773 | PI-103 | PI-103 is a potent, ATP-competitive PI3K,cell-permeable,inhibitor.The IC50 values are 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γrespectively. |
| M30922 | PI-273 | PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis. |
| M30890 | BGT226 | BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells. |
| M28980 | PI4KIIIbeta-IN-10 | PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC50 of 3.6 nM. |
| M28374 | GSK-A1 | GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research. |
| M28338 | GSK-F1 | GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research. |
| M25548 | MOMIPP | MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB). |
| M20759 | 3-Hydroxyanthranilic acid | 3-Hydroxyanthranilic Acid (3-HAA, 3-HANA), a tryptophan metabolite, has an immunomodulatory effect that may result from inhibition of PI3K/Akt/mTOR and NF-κB activity, thereby decreasing the production of pro-inflammatory mediators. |
| M18682 | Heterophyllin B | Heterophyllin B is an active cyclic peptide isolated from Pseudostellaria heterophylla. |
| M17862 | Lupenone | Lupenone plays a role through the PI3K/Akt/mTOR and NF-κB signaling pathways. Lupenone has anti-inflammatory, antiviral, antidiabetic and anticancer activities. |
| M14860 | PI4KIIIbeta-IN-9 | PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC50 of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC50s of 152 nM and 1046 nM, respectively. |
| M14856 | Quercetin dihydrate | Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively. |
| M14854 | PI3K/mTOR Inhibitor-2 | PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR. Antitumor activity. |
| M14853 | Pilaralisib analogue | Pilaralisib analogue (XL147 analogue) is a representative and selective PI3Kα inhibitor. |
| M14848 | Copanlisib dihydrochloride | Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. |
| M14845 | AZD8186 | AZD8186 is a PI3K inhibitor, which potently inhibits PI3Kβ (IC50=4 nM) and PI3Kδ (IC5050=12 nM) with selectivity over PI3Kα (IC50=35 nM) and PI3Kγ (IC50=675 nM). |
| M11405 | Inavolisib (GDC-0077) | Inavolisib (GDC-0077; RG6114) is a potential best-in-class, orally selective PI3Kα inhibitor (IC50=0.038 nM). GDC-0077 (RG6114) exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. GDC-0077 (RG6114) is more selective for mutants compared to wild-type PI3Kα. It can trigger the degradation of mutation-producing PIK3α. |
| M11310 | Zandelisib | Zandelisib (ME-401) is a PI3K inhibitor that selectively inhibits P110 δ with an IC50 value of 3.5 nM. Zandelisib has antitumor effects. |
| M10443 | Linperlisib (YY-20394) | Linperlisib, also known as YY-20394 and PI3Kδ-IN-2, is a potent and selective PI3Kδ inhibitor. |
| M10186 | Leniolisib | Leniolisib (CDZ173) is a first-in-class (first-in-class), potent, selective PI3Kδ inhibitor with an IC50 value of 11 nM. Leniolisib has the potential for immunodeficiency disorders treatment. |
| M10157 | Seletalisib | Seletalisib (UCB5857) is a potent and selective PI3Kδ inhibitor, with IC50 of 12 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
